reslizumabi

Reslizumab is a humanized monoclonal antibody used in the treatment of severe eosinophilic asthma. It targets interleukin-5 (IL-5), a cytokine that plays a crucial role in the growth, activation, and survival of eosinophils. By binding to IL-5, reslizumab inhibits its interaction with eosinophils, thereby reducing their numbers and activity in the airways.

The efficacy and safety of reslizumab have been evaluated in several clinical trials. It is administered intravenously and is typically used as an add-on therapy for patients with a history of exacerbations or oral corticosteroid dependence. The drug works by reducing the frequency of asthma exacerbations and improving lung function.

Common side effects associated with reslizumab include nasopharyngitis, hypersensitivity reactions, and upper respiratory tract infections. Severe hypersensitivity reactions, including anaphylaxis, have been reported, necessitating careful monitoring during and after administration.

Reslizumab is approved in certain regions for the treatment of severe eosinophilic asthma. Its use is generally reserved for patients who have not achieved adequate control with standard asthma therapies. The decision to use reslizumab should be made by a healthcare professional based on an individual patient's clinical presentation and response to treatment. Ongoing research continues to explore its potential applications and long-term effects.